ClinicalTrials.gov
ClinicalTrials.gov Menu

The Effects of GIP and GLP-2 on the Secretion of Glucagon in Patients With Type 1 Diabetes

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00732602
Recruitment Status : Completed
First Posted : August 12, 2008
Last Update Posted : February 13, 2009
Sponsor:
Collaborator:
University of Copenhagen
Information provided by:
University Hospital, Gentofte, Copenhagen

Brief Summary:
The purpose of this study is to determine whether Glucose-dependent Insulinotropic Polypeptide (GIP) or Glucagon Like Peptide 2 (GLP-2) has an affect on the secretion of Glucagon from the pancreas in patients with type 1 diabetes mellitus.

Condition or disease Intervention/treatment Phase
Diabetes Mellitus Other: GIP-infusion Other: Sodium-chloride Other: GLP-2 infusion Not Applicable

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 8 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Single (Participant)
Primary Purpose: Basic Science
Official Title: The Effects of GIP and GLP-2 on the Secretion of Glucagon in Patients With Type 1 Diabetes
Study Start Date : January 2008
Actual Primary Completion Date : August 2008

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Diabetes Type 1
Drug Information available for: Glucagon
U.S. FDA Resources

Arm Intervention/treatment
Active Comparator: B
GLP-2 infusion
Other: GLP-2 infusion
Placebo Comparator: C
Sodium-chloride infusion
Other: Sodium-chloride
Active Comparator: A
GIP-infusion
Other: GIP-infusion



Primary Outcome Measures :
  1. plasma-glucagon Area Under Curve at 0-90 min. and 90-180 min.


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Caucasians over 18 years with type 1 diabetes (WHO criteria)
  • Arginine test without rise in plasma C-peptide
  • Normal blood Hemoglobin
  • Informed consent

Exclusion Criteria:

  • Liver disease
  • Diabetic nephropathy
  • Treatment with medications unpausable for 12 hours

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00732602


Locations
Denmark
University Hospital, Gentofte
Hellerup, Capital Region, Denmark, 2900
Sponsors and Collaborators
University Hospital, Gentofte, Copenhagen
University of Copenhagen

Responsible Party: Mikkel Christensen MD, University Hospital, Gentofte, Copenhagen
ClinicalTrials.gov Identifier: NCT00732602     History of Changes
Other Study ID Numbers: H-D-2007-0058
First Posted: August 12, 2008    Key Record Dates
Last Update Posted: February 13, 2009
Last Verified: February 2009

Keywords provided by University Hospital, Gentofte, Copenhagen:
Glucagon
Glucose-dependent Insulinotropic Polypeptide
Glucagon-Like peptide 2

Additional relevant MeSH terms:
Diabetes Mellitus
Diabetes Mellitus, Type 1
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Autoimmune Diseases
Immune System Diseases
Glucagon
Gastric Inhibitory Polypeptide
Glucagon-Like Peptide 1
Gastrointestinal Agents
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Incretins